echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Sino-U.S. Double News: China Biopharmaceuticals declares P2X3 receptor antagonist to treat chronic cough

    Sino-U.S. Double News: China Biopharmaceuticals declares P2X3 receptor antagonist to treat chronic cough

    • Last Update: 2021-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 14, the TCR1672 tablet of Beijing Tide, a subsidiary of China National Biopharmaceutical Co.


    The P2X3 receptor is a ligand-gated ion channel in the purinergic receptor family


    TCR1672 blocks the calcium influx produced by the P2X3 receptor by blocking adenosine triphosphate (ATP), thereby exerting a specific inhibitory effect on it to achieve a therapeutic effect


    Intractable chronic cough refers to a cough in which the cause cannot be clarified after a comprehensive examination, or the cough has not been significantly relieved after conventional treatment


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.